DE69739775D1 - Verabreichung von Produkten des 5-lipoxygenase Synthesewegs zur Behandlung von mikrobiellen Infektionen - Google Patents

Verabreichung von Produkten des 5-lipoxygenase Synthesewegs zur Behandlung von mikrobiellen Infektionen

Info

Publication number
DE69739775D1
DE69739775D1 DE69739775T DE69739775T DE69739775D1 DE 69739775 D1 DE69739775 D1 DE 69739775D1 DE 69739775 T DE69739775 T DE 69739775T DE 69739775 T DE69739775 T DE 69739775T DE 69739775 D1 DE69739775 D1 DE 69739775D1
Authority
DE
Germany
Prior art keywords
products
treatment
administration
microbial infections
synthesis pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739775T
Other languages
English (en)
Inventor
Marc Peters-Golden
Theodore Standiford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Application granted granted Critical
Publication of DE69739775D1 publication Critical patent/DE69739775D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69739775T 1996-12-03 1997-12-03 Verabreichung von Produkten des 5-lipoxygenase Synthesewegs zur Behandlung von mikrobiellen Infektionen Expired - Lifetime DE69739775D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/757,136 US5909734A (en) 1996-12-03 1996-12-03 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense

Publications (1)

Publication Number Publication Date
DE69739775D1 true DE69739775D1 (de) 2010-04-01

Family

ID=25046516

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69734476T Expired - Lifetime DE69734476T2 (de) 1996-12-03 1997-12-03 Verabreichung von produkten des 5-lipoxygenasestoffwechsels zur steigerung der antimikrobiellen abwehr
DE69739775T Expired - Lifetime DE69739775D1 (de) 1996-12-03 1997-12-03 Verabreichung von Produkten des 5-lipoxygenase Synthesewegs zur Behandlung von mikrobiellen Infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69734476T Expired - Lifetime DE69734476T2 (de) 1996-12-03 1997-12-03 Verabreichung von produkten des 5-lipoxygenasestoffwechsels zur steigerung der antimikrobiellen abwehr

Country Status (9)

Country Link
US (3) US5909734A (de)
EP (2) EP1037640B1 (de)
AT (2) ATE307589T1 (de)
AU (1) AU733567B2 (de)
CA (1) CA2278140C (de)
DE (2) DE69734476T2 (de)
DK (1) DK1037640T3 (de)
ES (2) ES2341255T3 (de)
WO (1) WO1998024397A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473708B2 (en) 1996-02-15 2009-01-06 Jean Gosselin Agents with leukotriene B4-like antiviral (enveloped RNA) activities
US5909734A (en) * 1996-12-03 1999-06-08 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
KR100325581B1 (ko) * 1998-08-07 2002-08-24 오우택 아라키토닉산의리폭시게네이즈대사결과물질을함유하는진통제용조성물
WO2004112795A1 (en) * 2003-06-25 2004-12-29 Ltb4 Sweden Ab Ltb4 compositions for treating tract infections
WO2005102309A2 (en) * 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
CN101039698B (zh) * 2004-09-20 2011-11-09 Ltb4瑞典公司 稳定的白三烯b4(ltb4)药剂的药学配方
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN112546196A (zh) * 2020-02-29 2021-03-26 中国人民解放军总医院第三医学中心 肌动蛋白聚合诱导剂在制备抵抗或抑制肺炎克雷伯氏菌的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4821714A (en) * 1986-12-04 1989-04-18 Smelser Danny N Pharmaceutical endotracheal tube
US5314918A (en) * 1987-06-24 1994-05-24 Smithkline Beecham Corporation Leukotriene antagonists
US5145861A (en) * 1987-11-04 1992-09-08 Merrell Dow Pharmaceuticals Inc. Fluorinated arachidonic acid derivatives
AU667300B2 (en) * 1992-03-07 1996-03-21 Morinaga Milk Industry Company Limited Immunostimulatory peptide from lactoferrin
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US5909734A (en) * 1996-12-03 1999-06-08 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense

Also Published As

Publication number Publication date
ATE307589T1 (de) 2005-11-15
EP1602375A3 (de) 2005-12-14
EP1602375B1 (de) 2010-02-17
CA2278140C (en) 2008-02-05
US20050267211A1 (en) 2005-12-01
DK1037640T3 (da) 2006-03-13
CA2278140A1 (en) 1998-06-11
WO1998024397A2 (en) 1998-06-11
US7696148B1 (en) 2010-04-13
US5909734A (en) 1999-06-08
EP1037640B1 (de) 2005-10-26
WO1998024397A3 (en) 1998-09-03
EP1037640A4 (de) 2003-07-23
ES2341255T3 (es) 2010-06-17
DE69734476D1 (de) 2005-12-01
AU733567B2 (en) 2001-05-17
ES2251748T3 (es) 2006-05-01
ATE457730T1 (de) 2010-03-15
EP1602375A2 (de) 2005-12-07
DE69734476T2 (de) 2006-07-13
AU5794298A (en) 1998-06-29
EP1037640A2 (de) 2000-09-27

Similar Documents

Publication Publication Date Title
GEP20053429B (en) 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
DE69802260D1 (de) Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
NZ506058A (en) Antibacterial 9-substituted tetracyclines, and pharmaceuticals and uses thereof
ATE407687T1 (de) Probiotisches milchsäurebakterium zur behandlung bakterieller infektionen in zusammenhang mit sids
WO2001058465A3 (en) Probiotic therapy for newborns
DE69731309D1 (de) Impfstofformel auf polynukleotidbasis zur behandlung von hundekrankheiten, insbesondere solcher des atmungs- und verdauungstraktes
HK1014155A1 (en) Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
NO991548L (no) Anvendelse av mupirocin for fremstilling av et medikament for behandling av bakterieinfeksjoner forÕrsaket i forbindelse med kolonisering av nasofarynks med patogene organismer
AU1794601A (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
DE69739775D1 (de) Verabreichung von Produkten des 5-lipoxygenase Synthesewegs zur Behandlung von mikrobiellen Infektionen
EE9700269A (et) Farmatseutiline kompositsioon, mis sisaldab Lactobacillus plantarum'it ja arginiini
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
ES2136206T3 (es) Composicion antibacteriana que contiene alfalactalbumina multimerica.
IL124733A0 (en) Composition for organ cryopreservation and treatment of viral and bacterial infections
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE602004017586D1 (de) Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus
HUP0003845A2 (hu) Antimikrobiális 8a-azalidok alkalmazása
Czarnecki et al. The use of mupirocin before skin surgery
RU94024111A (ru) Способ профилактики кишечных инфекций
MX9708385A (es) Derivados novedosos de tetraciclina, composiciones que los contienen, y el uso de las mismas.
RU94024117A (ru) Способ лечения гастроэнтероколита
Dusmagambetov et al. Microflora in patients with complicated forms of acute cholecystitis treated by low-frequency ultrasonics and sulfacrylate glue
LT98090A (en) Composition for organ cryopreservation and treatment of viral and bacterial infections
UA22243A (uk) Спосіб лікуваhhя локальhих гhійhо-запальhих захворюваhь

Legal Events

Date Code Title Description
8364 No opposition during term of opposition